Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17902991 | 1.00 | CTSS (0.52) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL12283739 | 1.00 | CTSS (0.52) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL17581833 | 1.00 | CTSS (0.52) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL13436631 | 1.00 | CTSS (0.52) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL23998665 | 0.97 | CTSS (0.51) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL23106074 | 0.92 | CTSK (0.50) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL29593613 | 0.91 | CTSK (0.53) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL25459969 | 0.90 | CTSK (0.48) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL17209941 | 0.90 | CTSK (0.48) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL28342732 | 0.90 | CTSK (0.48) | CTSSCTSKMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-12570692-B2 | Oligopeptide linker intermediate and preparation method thereof | MABPLEX INTERNATIONAL CO., LTD. (CN) | 2026-03-10 | — | — | US | disclosed |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-20260053939-A1 | Combination Therapy for Cancer | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-02-26 | — | — | US | disclosed |
| EP-4673474-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | disclosed |
| EP-4659809-A2 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4652183-A1 | PEPTIDE-DRUG CONJUGATES FOR TARGETED THERAPY OF RENAL DISEASES | Shanghai MicuRx Pharmaceutical Co., Ltd. (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| EP-4634202-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| WO-2015095953-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2015-07-02 | — | — | WO | disclosed |
| WO-2015095953-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2015-07-02 | — | — | WO | disclosed |
| WO-2014100762-A9 | HYDROPHILIC SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | BIOLLIANCE C.V. (NL) | 2014-11-06 | — | — | WO | disclosed |
| US-20140193437-A1 | HYDROPHILIC SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | BIOALLIANCE C.V. (NL) | 2014-07-10 | — | — | US | disclosed |
| WO-2014067960-A2 | FUNCTIONALIZED 9-BROMO-CAMPTOTHECIN DERIVATIVES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-05-08 | — | — | WO | disclosed |
| US-8399403-B2 | drug-ligand conjugates that are potent cytotoxins; stabilized therapeutic agents and markers; exhibit high specificity of action, reduced toxicity, and improved stability in blood ; antitumors | MEDAREX, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100092496-A1 | CHEMICAL LINKERS AND CONJUGATES THEREOF | MEDAREX, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7691962-B2 | Chemical linkers and conjugates thereof | MEDAREX, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | MEDAREX, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | MEDAREX, INC. (US) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053939-A1 | Combination Therapy for Cancer | BCL6, PSMB6, PDCD6 | CTSS 4112/4885CTSK 3523/4885MEN1 1303/4885 |
| US-12570692-B2 | Oligopeptide linker intermediate and preparation method thereof | VIP, AQP4, EPCAM | CTSS 4066/4885CTSK 3236/4885MEN1 1761/4885 |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | CTSS 2817/4885CTSK 3327/4885MEN1 1082/4885 |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MET, BCL3, BCL9 | CTSS 3241/4885CTSK 2251/4885MEN1 569/4885 |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | FCGR2A, FCGR3B, BCL3 | CTSS 977/4885CTSK 2216/4885MEN1 4097/4885 |
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | CD47, ANTXR2, CD2BP2 | CTSS 1961/4885CTSK 1343/4885MEN1 2114/4885 |
| US-20140193437-A1 | HYDROPHILIC SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | CD44, ABCG2, MCL1 | CTSS 1193/4885CTSK 1437/4885MEN1 1079/4885 |
| US-20100092496-A1 | CHEMICAL LINKERS AND CONJUGATES THEREOF | CLSPN, CD74, ANTXR2 | CTSS 1077/4885CTSK 1012/4885MEN1 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.